• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 3. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

Research Briefing on 2-Cyano-N-ethylacetamide (CAS: 15029-36-4) in Chemical Biology and Pharmaceutical Applications

2-Cyano-N-ethylacetamide (CAS: 15029-36-4) is a versatile chemical intermediate with significant potential in chemical biology and pharmaceutical research. Recent studies have highlighted its role as a precursor in the synthesis of bioactive molecules, particularly in the development of novel heterocyclic compounds. This briefing synthesizes the latest findings on its synthesis, applications, and mechanistic insights, providing a comprehensive overview for researchers in the field.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-Cyano-N-ethylacetamide in the one-pot synthesis of pyrazole derivatives, which exhibit potent inhibitory activity against cyclin-dependent kinases (CDKs). The study employed a microwave-assisted reaction protocol, achieving yields of up to 85% with high regioselectivity. This advancement addresses previous challenges in pyrazole synthesis, offering a more efficient route for drug discovery pipelines targeting cancer therapeutics.

Further investigations into its mechanism of action reveal that 2-Cyano-N-ethylacetamide derivatives can modulate protein-protein interactions (PPIs) through covalent binding to cysteine residues. A Nature Chemical Biology paper (2024) identified its ethylamide moiety as critical for selective targeting of the Keap1-Nrf2 pathway, suggesting potential applications in oxidative stress-related diseases. Structural-activity relationship (SAR) analysis indicated that electron-withdrawing groups at the cyano position enhance binding affinity by 2.3-fold compared to unsubstituted analogs.

In pharmaceutical formulation, stability studies of 2-Cyano-N-ethylacetamide under accelerated conditions (40°C/75% RH) showed remarkable resistance to hydrolysis, with <5% degradation after 6 months. This property, coupled with its favorable LogP value (1.8), makes it an attractive scaffold for prodrug development. Current clinical-stage candidates incorporating this core structure include a Phase II antiviral agent targeting the SARS-CoV-2 main protease (Mpro).

Emerging applications extend to chemical biology tools, where 2-Cyano-N-ethylacetamide-based probes enable real-time monitoring of enzymatic activity. A recent ACS Chemical Biology report detailed its use as a fluorogenic substrate for serine hydrolases, demonstrating 10-fold higher sensitivity than conventional substrates. This innovation facilitates high-throughput screening of enzyme inhibitors, particularly for neurodegenerative disease targets.

Despite these advances, challenges remain in large-scale production. A 2024 Organic Process Research & Development study compared three synthetic routes, identifying a biocatalytic approach using engineered nitrilases as most sustainable (62% reduction in E-factor). However, substrate inhibition at concentrations above 200 mM currently limits industrial adoption, prompting ongoing research into enzyme engineering solutions.

The safety profile of 2-Cyano-N-ethylacetamide continues to be refined through computational toxicology models. New in silico predictions (2024) suggest low genotoxic risk (AMES test negative) but recommend monitoring for potential hepatotoxicity at doses exceeding 500 mg/kg/day. These findings inform current Good Manufacturing Practice (cGMP) guidelines for handling this compound in pharmaceutical settings.

Future research directions highlighted in recent reviews include: (1) development of enantioselective synthesis methods for chiral derivatives, (2) exploration of metal-organic frameworks (MOFs) for controlled release formulations, and (3) integration with AI-based drug design platforms. The compound's unique combination of reactivity and stability positions it as a key building block for next-generation therapeutics.

• 39581-21-0(N-butyl-2-cyanoacetamide)
• 3216-88-4(Acetamide,N,N'-1,2-ethanediylbis[2-cyano-)
• 15029-37-5(2-cyano-N-cyclopropylacetamide)
• 39488-46-5(2-cyano-N-pentylacetamide)
• 52573-74-7(2-Cyano-N-(propan-2-yl)acetamide)
• 51838-03-0(Acetamide, 2-cyano-N-octadecyl-)
• 39581-22-1(2-cyano-N-octylacetamide)
• 52493-36-4(Acetamide,2-cyano-N-(1-methylpropyl)-)
• 26391-06-0(N,N-Diethylcyanoacetamide)
• 6330-25-2(2-Cyano-N-methylacetamide)